protein

LIMP2 Peptide

MBS152054

0.05 mg

140 USD

Blocking Peptide

LIMP2 Peptide

[LIMP2]

[AMRF; EPM4; LGP85; CD36L2; HLGP85; LIMP-2; LIMPII; SR-BII; LIMP2; Lysosome membrane protein 2; 85 kDa lysosomal membrane sialoglycoprotein; scavenger receptor class B, member 2]

[Scavenger receptor class B, member 2; Lysosome membrane protein 2; lysosome membrane protein 2; LIMP II; CD36 antigen-like 2; lysosome membrane protein II; 85 kDa lysosomal membrane sialoglycoprotein; 85 kDa lysosomal sialoglycoprotein scavenger receptor class B, member 2; CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II); scavenger receptor class B, member 2; 85 kDa lysosomal membrane sialoglycoprotein; LGP85; CD36 antigen-like 2; Lysosome membrane protein II; LIMP II; Scavenger receptor class B member 2; CD_antigen: CD36]

[SCARB2]

[SCARB2; SCARB2; AMRF; EPM4; LGP85; CD36L2; HLGP85; LIMP-2; LIMPII; SR-BII; CD36L2; LIMP2; LIMPII; LGP85; LIMP II]

SCRB2_HUMAN

478

Liquid

200 ug/mL

Store LIMP2 peptide at -20°C, stable for one year.

Blocking (BL)

LIMP2 peptide is used for blocking the activity of CSN8 antibody.

Western Blot (WB)

Testing Data (TD)

Species: Human. Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Location: 16 amino acids near the center of human LIMP2.

18257312

AAH21892

Q14108

Lysosome Pathway (99052); Lysosome Pathway (96865)

The protein encoded by this gene is a type III glycoprotein that is located primarily in limiting membranes of lysosomes and endosomes. Earlier studies in mice and rat suggested that this protein may participate in membrane transportation and the reorganization of endosomal/lysosomal compartment. The protein deficiency in mice was reported to impair cell membrane transport processes and cause pelvic junction obstruction, deafness, and peripheral neuropathy. Further studies in human showed that this protein is a ubiquitously expressed protein and that it is involved in the pathogenesis of HFMD (hand, foot, and mouth disease) caused by enterovirus-71 and possibly by coxsackievirus A16. Mutations in this gene caused an autosomal recessive progressive myoclonic epilepsy-4 (EPM4), also known as action myoclonus-renal failure syndrome (AMRF). Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Feb 2011]

SCARB2: Acts as a lysosomal receptor for glucosylceramidase (GBA) targeting. Defects in SCARB2 are the cause of progressive myoclonic epilepsy type 4 with or without renal failure (EPM4). An autosomal recessive progressive myoclonic epilepsy associated with renal failure in some cases. Cognitive function is preserved. Myoclonus is a brief, involuntary twitching of a muscle or a group of muscles. Cognitive function is preserved. Genetic variants in SCARB2 can act as modifier of the phenotypic expression and severity of Gaucher disease. Belongs to the CD36 family. Protein type: Membrane protein, multi-pass; Membrane protein, integral; Receptor, misc. Chromosomal Location of Human Ortholog: 4q21.1. Cellular Component: lysosomal lumen; focal adhesion; membrane; lysosomal membrane; integral to membrane. Molecular Function: protein binding; enzyme binding; receptor activity. Biological Process: protein targeting to lysosome; cell adhesion. Disease: Epilepsy, Progressive Myoclonic 4, With Or Without Renal Failure

0.05 mg

140 USD